Merck announced the expansion of its high-potent active pharmaceutical ingredient (HPAPI) and antibody-drug conjugate (ADC) production capabilities and capacity at…
French pharmaceutical company Sanofi Pasteur has unveiled plans to build a new vaccine manufacturing facility in Toronto, Ontario, Canada.
Sanofi will invest more than €350m ($432m) in the state-of-the-art vaccine plant, which is the company’s largest facility-based investment to date.
The project was announced in April 2018 and construction is expected to be completed in 2021. The new facility is expected to commence operations in 2023 and will double the company’s vaccines output.
The new facility will enable Sanofi to support its paediatric and booster vaccines capacity to meet growing demand in the market. It will also strengthen the company’s Canadian operations.
The project is expected to provide up to 1,250 jobs.
Sanofi’s vaccine manufacturing facility location
Sanofi’s vaccine manufacturing facility will be located at Sanofi Pasteur’s Connaught Campus in North Toronto, which is the company’s headquarters for Canadian vaccine production and research and development (R&D).
Canada was selected as the ideal location for the new facility due to its strong legacy in vaccine R&D.
Sanofi’s vaccine manufacturing facility details
With a built-up area of 150,000ft², the new plant will feature equipment to manufacture tetanus vaccines and the antigens needed for the treatment of diphtheria. It will also manufacture five-component acellular pertussis (5-acP) antigen, which was researched and developed in Canada.
There is a growing demand for vaccines indicated for the treatment of whooping cough in children and adults. The new vaccine manufacturing facility will enable Sanofi to launch the whooping cough vaccine in more than 30 international markets.
Financing for Sanofi’s vaccine manufacturing facility
Sanofi’s vaccine manufacturing facility will receive C$70m ($55.5m) from the governments of Canada and Ontario.
A total of C$20m ($15.8m) from the $70m funding will be provided by the federal economic development agency for Southern Ontario (FedDev Ontario) through the Advanced Manufacturing Fund (AMF), a development programme that supports Ontario’s manufacturing sector.
The remaining C$50m ($39.7m) will be provided by the Government of Ontario through the Jobs and Prosperity Fund, which was created to promote R&D activity and finance projects related to pharmaceutical research in the state.
Sanofi has also requested the Economic Development Committee of Ontario to approve a property tax incentive under the Imagination, Manufacturing, Innovation and Technology (IMIT) programme, a business incentive programme that encourages new investment and employment.
Details of Sanofi Pasteur’s Toronto campus
Sanofi’s Toronto campus was initially founded as Antitoxin Laboratory in 1914 within the University of Toronto. It was later expanded by opening a pharmaceutical farm in North Toronto in 1917.
The company’s Toronto campus specialises in the development and manufacture of life-saving medicines for the US, Canada and other international markets. Spread across 54 acres, the campus includes office space, R&D labs and various vaccine manufacturing facilities. It employs approximately 1,400 people in industrial and commercial operations, and R&D.
The Toronto site manufactures nine products for serious bacterial infections such as pertussis, diphtheria and tetanus. Vaccines manufactured for these diseases include Pentacel®, Pediacel®, Adacel®, Adacel®-Polio, Quadracel®, Daptacel®, Td Adsorbed, Td Polio Adsorbed, and Tubersol®.
Thermo Fisher Scientific opened a new manufacturing facility in Lenexa, Kansas to meet the increasing demand for viral transport media…
Bushu Pharmaceuticals unveiled a new expansion programme for its pharmaceutical manufacturing facility in Misato, Japan, in August 2020. With the…